Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.
2016
13
LTM Revenue $4.7M
LTM EBITDA n/a
$49.6M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Nutriband has a last 12-month revenue of $4.7M and a last 12-month EBITDA of n/a.
In the most recent fiscal year, Nutriband achieved revenue of $2.1M and an EBITDA of -$5.1M.
Nutriband expects next 12-month revenue of XXX   and NTM EBITDA of XXX
See Nutriband valuation multiples based on analyst estimatesFY 2023 | FY 2024 | FY 2025 | LTM | NTM | |
---|---|---|---|---|---|
Revenue | $2.1M | $2.1M | XXX | XXX | XXX |
Gross Profit | $0.5M | $0.8M | XXX | XXX | XXX |
Gross Margin | 24% | 36% | XXX | XXX | XXX |
EBITDA | -$4.1M | -$5.1M | XXX | XXX | XXX |
EBITDA Margin | -197% | -246% | XXX | XXX | XXX |
Net Profit | -$6.2M | -$4.5M | XXX | XXX | XXX |
Net Margin | -297% | -215% | XXX | XXX | XXX |
Net Debt | n/a | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of April 15, 2025, Nutriband's stock price is $5.
Nutriband has current market cap of $55.1M, and EV of $49.6M.
See Nutriband trading valuation dataEV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
---|---|---|---|---|---|---|
$49.6M | $55.1M | XXX | XXX | XXX | XXX | $-0.59 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Sign UpAs of April 15, 2025, Nutriband has market cap of $55.1M and EV of $49.6M.
Nutriband's trades at 10.6x LTM EV/Revenue multiple, and n/a LTM EBITDA.
Analysts estimate Nutriband's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See valuation multiples for Nutriband and 10K+ public compsFY 2024 | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|
EV | $49.6M | XXX | XXX | XXX |
EV/Revenue | 21.8x | XXX | XXX | XXX |
EV/EBITDA | n/a | XXX | XXX | XXX |
P/E | -8.8x | XXX | XXX | XXX |
P/E/Growth | n/a | XXX | XXX | XXX |
EV/FCF | n/a | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Sign UpNutriband's NTM/LTM revenue growth is 552%
Nutriband's revenue per employee for the last fiscal year averaged $0.2M, while opex per employee averaged $0.4M for the same period.
Over next 12 months, Nutriband's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .
Analysts estimate Nutriband's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
See operational valuation multiples for Nutriband and other 10K+ public compsFY 2024 | NTM | FY 2025E | FY 2026E | FY 2027E | |
---|---|---|---|---|---|
Revenue Growth | 0% | XXX | XXX | XXX | XXX |
EBITDA Margin | n/a | XXX | XXX | XXX | XXX |
EBITDA Growth | 25% | XXX | XXX | XXX | XXX |
Rule of 40 (SaaS-only) | n/a | XXX | XXX | XXX | XXX |
Revenue per Employee | $0.2M | XXX | XXX | XXX | XXX |
Opex per Employee | $0.4M | XXX | XXX | XXX | XXX |
S&M Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
G&A Expenses to Revenue | n/a | XXX | XXX | XXX | XXX |
R&D Expenses to Revenue | 94% | XXX | XXX | XXX | XXX |
Opex to Revenue | 275% | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
EV/Revenue | EV/EBITDA | |||||
---|---|---|---|---|---|---|
2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Nutriband acquired XXX companies to date.
Last acquisition by Nutriband was XXXXXXXX, XXXXX XXXXX XXXXXX . Nutriband acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiplesAcquired Company | EV | EV/Revenue | EV/EBITDA |
---|---|---|---|
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Sign UpWhen was Nutriband founded? | Nutriband was founded in 2016. |
Where is Nutriband headquartered? | Nutriband is headquartered in United States of America. |
How many employees does Nutriband have? | As of today, Nutriband has 13 employees. |
Who is the CEO of Nutriband? | Nutriband's CEO is Mr. Gareth Sheridan. |
Is Nutriband publicy listed? | Yes, Nutriband is a public company listed on NAS. |
What is the stock symbol of Nutriband? | Nutriband trades under NTRB ticker. |
When did Nutriband go public? | Nutriband went public in 2017. |
Who are competitors of Nutriband? | Similar companies to Nutriband include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
What is the current market cap of Nutriband? | Nutriband's current market cap is $55.1M |
What is the current revenue of Nutriband? | Nutriband's last 12-month revenue is $4.7M. |
What is the current EV/Revenue multiple of Nutriband? | Current revenue multiple of Nutriband is 10.6x. |
What is the current revenue growth of Nutriband? | Nutriband revenue growth between 2023 and 2024 was 0%. |
Is Nutriband profitable? | Yes, Nutriband is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.